Clinicopathological significance of E-cadherin, !-catenin and p53 expression in gastric adenocarinoma

Abstract

<font face="TimesNewRoman,Bold" size="1"><font face="TimesNewRoman,Bold" size="1"><ul><li><div align="left"><strong>BACKGROUND</strong>: <font face="TimesNewRoman" size="2"><font face="TimesNewRoman" size="2">E-cadherin/catenin complexes exert a role in cell adhesion. </font></font><font face="+TimesNewRoman" size="2"><font face="+TimesNewRoman" size="2">'</font></font><font face="TimesNewRoman" size="2"><font face="TimesNewRoman" size="2">-catenin is a key player in Wnt signaling pathway in gastric cancer. P53 is a tumor suppressor gene which also regulates apoptosis. We assessed the expression of E-cadherin, </font></font><font face="+TimesNewRoman" size="2"><font face="+TimesNewRoman" size="2">'</font></font><font face="TimesNewRoman" size="2"><font face="TimesNewRoman" size="2">-catenin and p53 in gastric adenocarcinoma, and their correlations with&nbsp; linicopathological features.</font></font></div></li><font face="TimesNewRoman,Bold" size="1"><font face="TimesNewRoman,Bold" size="1"><li><div align="left"><strong>METHODS</strong>: <font face="TimesNewRoman" size="2"><font face="TimesNewRoman" size="2">Fifty six formalin-fixed, paraffin-embedded archival specimens of gastric adenocarcinoma were&nbsp; andomly included as cases. Adjacent tumor-free gastric mucosa of different premalignant stages was obtained from the cases. Immunohistochemical staining was performed to assess E-cadherin, </font></font><font face="+TimesNewRoman" size="2"><font face="+TimesNewRoman" size="2">'</font></font><font face="TimesNewRoman" size="2"><font face="TimesNewRoman" size="2">-catenin and p53 expression.</font></font></div></li></font></font><font face="TimesNewRoman,Bold" size="1"><font face="TimesNewRoman,Bold" size="1"><li><div align="left"><strong>RESULTS</strong>: <font face="TimesNewRoman" size="2"><font face="TimesNewRoman" size="2">All chronic atrophic gastritis and intestinal metaplasia revealed normal membranous staining. Only one patient with dysplasia had abnormal expression of E-cadherin and </font></font><font face="+TimesNewRoman" size="2"><font face="+TimesNewRoman" size="2">'</font></font><font face="TimesNewRoman" size="2"><font face="TimesNewRoman" size="2">-Catenin. Abnormal E-cadherin, </font></font><font face="+TimesNewRoman" size="2"><font face="+TimesNewRoman" size="2">'</font></font><font face="TimesNewRoman" size="2"><font face="TimesNewRoman" size="2">-catenin and p53 expression was found in 50%, 48.2% and 76.8% of cancer specimens respectively. Abnormal expression of E-cadherin was significantly correlated with aberrant </font></font><font face="+TimesNewRoman" size="2"><font face="+TimesNewRoman" size="2">'</font></font><font face="TimesNewRoman" size="2"><font face="TimesNewRoman" size="2">-catenin expression. Abnormal E-cadherin and </font></font><font face="+TimesNewRoman" size="2"><font face="+TimesNewRoman" size="2">'</font></font><font face="TimesNewRoman" size="2"><font face="TimesNewRoman" size="2">-catenin expression were significantly correlated with depth of tumor invasion and advanced gastric cancer (p < 0.05), lower degree of differentiation and diffused tumor type (p < 0.001). Node metastasis was not influenced by abnormal expression of E-cadherin and </font></font><font face="+TimesNewRoman" size="2"><font face="+TimesNewRoman" size="2">'</font></font><font face="TimesNewRoman" size="2"><font face="TimesNewRoman" size="2">-catenin. P53 was not associated with clinicopathological variables.</font></font></div></li></font></font><font face="TimesNewRoman,Bold" size="1"><font face="TimesNewRoman,Bold" size="1"><li><div align="left"><strong>CONCLUSIONS</strong>: <font face="TimesNewRoman" size="2"><font face="TimesNewRoman" size="2">Abnormal expression of the E-cadherin and </font></font><font face="+TimesNewRoman" size="2"><font face="+TimesNewRoman" size="2">'</font></font><font face="TimesNewRoman" size="2"><font face="TimesNewRoman" size="2">-catenin were associated with each other and influenced by histogenesis of gastric cancer and malignant behavior of tumor but not significant in premalignant lesions. They are more frequent in diffuse type and associated with advanced gastric cancer. P53 alterations are more frequent in the Iranian population compared with others.</font></font></div></li></font></font><font face="TimesNewRoman,Bold" size="1"><font face="TimesNewRoman,Bold" size="1"><li><div align="left"><strong>KEYWORDS</strong>: <font face="TimesNewRoman" size="2"><font face="TimesNewRoman" size="2">Gastric Cancer, E-cadherin, </font></font><font face="+TimesNewRoman" size="2"><font face="+TimesNewRoman" size="2">'</font></font><font face="TimesNewRoman" size="2"><font face="TimesNewRoman" size="2">-catenin, p53, Immunohistochemistry.</font></font></div></li></font></font></ul></font></font>

Keywords

• Gastric Cancer, E-cadherin, '-catenin, p53, Immunohistochemistry.